Holen Sie sich die Stockscreener-App
18.25
0.76%
-0.15
Handel nachbörslich:
18.25
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics to present at August biotech conferences on its chronic cough therapy Haduvio™ - Pluang
Trevi Therapeutics to Participate in Upcoming August Conferences - Yahoo Finance
Trevi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRVI - TradingView
Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
TRVI|Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355 - TradingKey
Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355 - TradingKey
Affinity Asset Advisors LLC Sells 150,000 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Siren L.L.C. Cuts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Fifth Third Bancorp Invests $1.53 Million in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Serina Therapeutics Appoints Farrell Simon to its Board of Directors - The Manila Times
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Rating Increased to Strong-Buy at BMO Capital Markets - MarketBeat
TRVI Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24 - Moomoo
BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target - marketscreener.com
Trevi Therapeutics Initiated at Outperform by BMO Capital - Moomoo
BMO Capital Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $36 - Moomoo
BMO initiates Trevi Therapeutics stock at Outperform, $36 target By Investing.com - Investing.com Canada
Trevi Therapeutics (NASDAQ:TRVI) Shares Down 5.1%Here's Why - MarketBeat
TRVI Maintains Buy by B. Riley Securities -- Price Target Raised to $31.00 - GuruFocus
B. Riley Financial Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
TRVI Maintains Buy Rating -- Price Target Raised to $24.00 by HC Wainwright - GuruFocus
B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating - marketscreener.com
HC Wainwright Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - GuruFocus
Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright - Investing.com
Trevi Therapeutics (TRVI) Is Up 6.9% After Haduvio Cough Data And New ILD Trial PlanHas The Bull Case Changed? - webull.com
TRVI Surges As Trevi Therapeutics Draws Fresh Bullish Momentum - timothysykes.com
TRVI Surges As Trevi Therapeutics Draws Aggressive Buyers - timothysykes.com
TRVI Jumps As Trevi Therapeutics Extends Rally On Heavy Interest - StocksToTrade
Trevi Therapeutics Stock Jumps As Momentum Traders Pile In - timothysykes.com
TRVI Jumps As Trevi Therapeutics Extends Bullish Run - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Trevi Therapeutics (NASDAQ:TRVI) Hits New 1-Year HighHere's Why - MarketBeat
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market - Yahoo Finance
Why Trevi Therapeutics (TRVI) Stock Is Up Today - Moomoo
Trevi climbs as GSK drops chronic cough therapy (TRVI:NASDAQ) - Seeking Alpha
TRVI Stock Firms Up As Haduvio Story Hits Center Stage - StocksToTrade
Trevi Therapeutics (TRVI) Sees Significant Price Increase - GuruFocus
Trevi Therapeutics (NASDAQ:TRVI) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Trevi Therapeutics Shares Surge 13% as Biopharma Investors Cheer Cough Drug Data at London Conference - International Business Times Australia
Stock Traders Buy Large Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.4%What's Next? - MarketBeat
Candriam S.C.A. Purchases Shares of 773,620 Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (TRVI) Slips 3% as Shares Approach Key Support at $16.95Earnings Quality Factor - dars.gov.et
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial - TipRanks
Trevi Therapeutics Inc. (TRVI) Q1 2026 Earnings: EPS Miss and No Revenue Highlight the Challenges of a Pre-Commercial BiotechEarnings Expansion Phase - DonanımHaber
SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics (TRVI) Slips Over 3% as Shares Test Key Support ZoneNHNL Ratio - dars.gov.et
TRVi stock stays tied to Trevi Therapeutics' clinical outlook - AD HOC NEWS
Price to earnings forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to sales forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to book forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Enterprise value to revenue forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to earnings forward of Trevi Therapeutics, Inc. – BOATS:TRVI - TradingView
2.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):